HomeCompareZYXI vs JNJ

ZYXI vs JNJ: Dividend Comparison 2026

ZYXI yields 3636.36% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZYXI wins by $136.98M in total portfolio value
10 years
ZYXI
ZYXI
● Live price
3636.36%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$137.01M
Annual income
$2,429,517.95
Full ZYXI calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ZYXI vs JNJ

📍 ZYXI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZYXIJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZYXI + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZYXI pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZYXI
Annual income on $10K today (after 15% tax)
$309,090.91/yr
After 10yr DRIP, annual income (after tax)
$2,065,090.26/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ZYXI beats the other by $2,061,104.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZYXI + JNJ for your $10,000?

ZYXI: 50%JNJ: 50%
100% JNJ50/50100% ZYXI
Portfolio after 10yr
$68.52M
Annual income
$1,217,103.67/yr
Blended yield
1.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ZYXI
Analyst Ratings
6
Buy
3
Hold
Consensus: Buy
Price Target
$14.38
+26045.5% upside vs current
Range: $11.00 — $18.00
Altman Z
-5.0
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZYXI buys
0
JNJ buys
0
No recent congressional trades found for ZYXI or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZYXIJNJ
Forward yield3636.36%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$137.01M$30.3K
Annual income after 10y$2,429,517.95$4,689.40
Total dividends collected$101.63M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$14.38$228.73

Year-by-year: ZYXI vs JNJ ($10,000, DRIP)

YearZYXI PortfolioZYXI Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$192,518$181,818.18$10,592$272.30+$181.9KZYXI
2$1,841,663$1,635,668.49$11,289$357.73+$1.83MZYXI
3$9,282,305$7,311,726.11$12,123$472.89+$9.27MZYXI
4$27,152,808$17,220,741.46$13,141$629.86+$27.14MZYXI
5$52,592,991$23,539,485.74$14,408$846.81+$52.58MZYXI
6$77,580,225$21,305,724.70$16,021$1,151.60+$77.56MZYXI
7$97,696,914$14,686,073.70$18,122$1,588.22+$97.68MZYXI
8$113,177,847$8,642,148.87$20,930$2,228.20+$113.16MZYXI
9$125,778,601$4,678,305.21$24,792$3,191.91+$125.75MZYXI
10$137,012,622$2,429,517.95$30,274$4,689.40+$136.98MZYXI

ZYXI vs JNJ: Complete Analysis 2026

ZYXIStock

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Full ZYXI Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ZYXI vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZYXI vs SCHDZYXI vs JEPIZYXI vs OZYXI vs KOZYXI vs MAINZYXI vs ABBVZYXI vs MRKZYXI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.